Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs

– Seasoned biopharma medical leader joins Apnimed as it initiates its Phase 3 clinical program for AD109, a potential new oral treatment for Obstructive Sleep Apnea CAMBRIDGE, Mass. September 18, 2023 – Apnimed, a clinical-stage pharmaceutical company focused on...

Apnimed to Participate in Upcoming Investor Conferences in September

CAMBRIDGE, Mass. August 30, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...

Fierce Biotech Names Apnimed a 2023 “Fierce 15” Biotech Company

CAMBRIDGE, Mass. August 28, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...